Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVELOPE: Enfortumab Vedotin for Advanced Small Bowel Adenocarcinoma After Platinum Therapy
jRCT2031250424Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in small bowel adenocarcinoma (SBA), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Objective response rate (centrally assessed). Started Nov 2026; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on jRCT2031250424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250424.